denali
therapeutics
host
webinar
transporting
biotherapeutics
across
barrier
nasdaq
dnli
webinar
scheduled
thursday
october
eastern
time
south
san
francisco
globe
newswire
denali
therapeutics
nasdaq
dnli
biopharmaceutical
company
developing
broad
portfolio
product
candidates
engineered
cross
barrier
bbb
treatment
neurodegenerative
diseases
today
announced
host
webinar
transporting
biotherapeutics
across
bbb
thursday
october
eastern
time
webinar
provide
deep
dive
denali
bbb
transport
vehicle
tv
technology
increase
exposure
therapeutics
brain
review
progress
tv
platform
therapeutics
portfolio
including
etv
ids
etv
sgsh
ptv
pgrn
atv
oligonucleotide
tv
otv
programs
neurodegenerative
diseases
well
potential
applications
outside
neurodegeneration
registration
live
webinar
accessible
investor
page
denali
website
following
webinar
replay
program
available
limited
time
accessible
address
denali
tv
platform
bbb
essential
maintaining
brain
microenvironment
protecting
harmful
substances
pathogens
circulating
bloodstream
historically
bbb
posed
significant
challenges
drug
development
central
nervous
system
cns
diseases
preventing
drugs
reaching
brain
therapeutically
relevant
concentrations
denali
tv
platform
proprietary
technology
designed
effectively
deliver
large
therapeutic
molecules
antibodies
enzymes
proteins
oligonucleotides
across
bbb
intravenous
administration
tv
technology
based
engineered
fc
fragments
bind
specific
natural
transport
receptors
expressed
bbb
delivered
brain
receptor
mediated
transcytosis
denali
research
shown
animal
models
antibodies
enzymes
engineered
tv
technology
demonstrated
greater
brain
exposure
similar
antibodies
enzymes
without
technology
improved
exposure
broad
distribution
brain
may
increase
therapeutic
efficacy
enabling
widespread
achievement
therapeutically
relevant
concentrations
product
candidates
advanced
program
based
tv
technology
etv
ids
hunter
syndrome
currently
phase
study
denali
therapeutics
denali
therapeutics
biopharmaceutical
company
developing
broad
portfolio
product
candidates
engineered
cross
barrier
bbb
neurodegenerative
diseases
denali
pursues
new
treatments
rigorously
assessing
genetically
validated
targets
engineering
delivery
across
bbb
guiding
development
biomarkers
demonstrate
target
pathway
engagement
denali
based
south
san
francisco
additional
information
please
visit
investor
relations
contact
laura
hansen
hansen
media
contacts
lizzie
hyland
lhyland
morgan
warners
mwarners
